JCI Insight – Cycling GLP-1 Receptor Agonist Treatment Induces Therapeutic Resistance and Increased Adiposity
To the Editor: GLP-1 receptor agonists (GLP-1 RAs) have revolutionized obesity management, yet “real-world” use is characterized by frequent treatment discontinuation and reinitiation (1, 2). More than half of patients discontinue therapy within 24 months, and many subsequently restart (1). Because weight regain is rapid following cessation, and up to 40% of GLP-1 RA-induced weight […]